May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
The Length of the New Vessels Regression in Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab
Author Affiliations & Notes
  • L. Bonavia
    Ophthalmology/H. SACCO, University of Milan, milano, Italy
  • S. De Angelis
    Ophthalmology/H. SACCO, University of Milan, Milano, Italy
  • C. Rosina
    Ophthalmology/H. SACCO, University of Milan, Milano, Italy
  • G. Staurenghi
    Ophthalmology/H. SACCO, University of Milan, Milano, Italy
  • Footnotes
    Commercial Relationships L. Bonavia, None; S. De Angelis, None; C. Rosina, None; G. Staurenghi, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 282. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Bonavia, S. De Angelis, C. Rosina, G. Staurenghi; The Length of the New Vessels Regression in Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):282.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To report the follow-up of retinal and/or disc neovascularization regression in Proliferative Diabetic Retinopathy (PDR) after intravitreal bevacizum

Methods:: Retrospective chart review of six eyes of six patients with retinal and/or disc neovascularitation secondary to diabetes mellitus. Patients received intravitreal bevacizumab (1.25 mg). Ophthalmic evaluations included nonstandardized Snellen visual acuity (VA), complete ophthalmic examination and fluorescein angiography every month.

Results:: At 1 month post injection all patients showed a complete neovascularization regression . At 3 months post injection the new-vessels reapper in 3 of 6 (50%) eyes, at 4 months post injection in 1of 6 eyes (1,66%), at 5 months post injection in 1 of 6 eyes (1,66%) and at 7 months post injection in 1of 6 eyes.

Conclusions:: The results suggest that intravitreal bevacizumab is well tolerated and associated with a rapid regression of retinal neovascularization secondary to PDR. Unfortunately the regression is not permanent and the neovascularitation come back (exactly in the same place) after 3-7 months (mean: 5.5).

Keywords: diabetic retinopathy • neovascularization • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×